C4 Therapeutics enters collaboration with Merck KGaA for two protein degraders; $16M upfront, up to $740M milestones

C4 Therapeutics, Inc.

Upfront payment of $16 million from Merck KGaA; Merck to fund discovery research costs.
C4T eligible for up to approximately $740 million in discovery, regulatory, and commercial milestone payments.
Tiered royalties on net sales: mid-single to low-double digit percent.
Collaboration on two targeted protein degraders from C4T's internal oncology pipeline.
Merck KGaA responsible for clinical development and commercialization; C4T uses TORPEDO platform.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

C4 Therapeutics, Inc. entered into Research Collaboration and License Agreement with Merck KGaA, Darmstadt, Germany (operating as EMD Serono in U.S. and Canada) valued at upfront cash payment of $16.0 million; aggregate potential milestone payments of approximately $740 (effective 2024-03-01).

Action: entry
Agreement: collaboration
Counterparty: Merck KGaA, Darmstadt, Germany (operating as EMD Serono in U.S. and Canada)
Value: upfront cash payment of $16.0 million; aggregate potential milestone payments of approximately $740
Effective: 2024-03-01

Exact text from the filing

On March 1, 2024 , C4 Therapeutics, Inc. (“ C4T ”) entered into a Research Collaboration and License Agreement (“ License Agreement ”) with Merck KGaA, Darmstadt, Germany (“ MKDG ”), which operates its healthcare business as EMD Serono in the U.S. and Canada, to exclusively discover two targeted protein degraders against critical oncogenic proteins that C4T has progressed within its internal discovery pipeline.

View on SEC.gov

737 material agreements filed in the last 30 days. Browse all material agreements →

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-008339

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.